Loading...

INAB IN8BIO INC Delisting Actions 8-K Filing

N8B

NB

IN8BIO INC

(INAB)

2025 8-K

Show Summary

Show Summary

Product Expansion

Reverse Stock Split

Financial Statements

Clinical Trials

Rights Offerings

Financial Results

Director Resignation

New Product Launch

Trial Data Update

Nasdaq Compliance Extension

Clinical Trial Update

Q3 Financial Results

Securities Agreement

Management Change

Executive Changes

Clinical Data Update

Financial Results and Delis...

Annual Meeting and Press Re...

Clinical Data Announcement

Earnings Reports

Financial Results Announcement

Private Placement

Clinical Update from Phase ...

Appointment of Director and...

Clinical Data Announcement

Financial Results Announcement

Financial Results Announcement

Annual Meeting Results

Other Special Situation

Earnings Reports

Appointment of Director

Press Release and Corporate...

Financial Results Announcement

Regulation FD Disclosure

External Links:

IN8bio, Inc. received a 180-day extension from Nasdaq to comply with the minimum bid price requirement for continued listing, now due by August 4, 2025, and has transferred its stock listing to the Nasdaq Capital Market; the company also announced it

AI Assistant

IN8BIO INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.